Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních věcí x. 58/2007 Xx. x. x., x. 46/2008 Xx. x. x. a x. 47/2012 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek a xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.1)
X xxxxx xxxxxx Přílohy I xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Úmluvy dne 1. xxxxx 2012 x xxxxx dnem xxxxxxxxx v platnost x xxx Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx znění Přílohy X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. ledna 2011 x vyhlášené xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x její xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx přijatá xxx 19. října 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX DOPINGU XX XXXXXX
Xxxxxxx X - Seznam xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX LÁTEK X XXXXX XXXXXXX XXX XXX 2012
SVĚTOVÝ XXXXXXXXXXXXX KODEX
Xxxxxx xx 1. xxxxx 2012
Podle xxxxxx 4.2.2 Xxxxxxxxx antidopingového xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx látky" xxxxx xxxxx ze xxxxxx X1, S2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, M2 x X3.
XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX) |
XXXXXXXX XXXXX
X0. XXXXXXXXXXX LÁTKY
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. léčiva x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, zahrnující:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-norandrosteron |
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol) | 19-xxxxxxxxxxxxxxxxx |
2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, ale xx x omezením xxxxx na xx.
Xxx účely xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx vztahuje x látce, xxxxxx xxxx není xxxxxxxx xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx. |
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX LÁTKY
Xxxxxxxxxxx látky a xxxxxx xxxxxxxxxx xxxxxxx xxxx zakázány:
1. Xxxxx stimulující xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (dEPO), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) u xxxx;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx faktory (XXXx), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxx podobný xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) a xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx degradaci bílkovin xxxxx, šlach a xxxxxx, krevní xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx;
x další látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 agonisté (xxxxxx xxxx xxxxxxxxxx optických xxxxxxx) xxxx zakázáni xxxxx xxxxxxxxxxx (maximálně 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 hodin) x salmeterolu xxxxx xxxx xxxxxx x xxxxxxxx x souladu x doporučeným léčebným xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x moči v xxxxxxxxxxx xxxxx xxx 30 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou studií, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx xxx xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (androstatriendion), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, formestan, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Proliferator Xxxxxxxxx Receptor δ (XXXXδ) agonists/ (xxxx. GW 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x součinnosti x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
X5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Xxxxxxxx:
Xxxxxxxxx, desmopressin, plasmaexpandery (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx x další xxxxx x podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxx felypressinu xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), triamteren x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Soutěž) jakéhokoliv xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, efedrin, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx látku xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx následující:
1. Krevní xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxx heterologní xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), perfluorochemikálie x xxxxxxxxxxx (RSR13), xxx ne x xxxxxxxx pouze xx xx. Dodávání xxxxxxx xxxxxxxx xxxx.
X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, za účelem xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků odebraných xxx Dopingové xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (např. proteázami) xxxx, ale xx x omezením xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxx 50 xx xx 6 xxxxx jsou xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx krve do xxxxxxxxx systému xx xxxxxxxx.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx sekvencí;
2. Xxxxxxx normálních xxxx xxxxxxxxx modifikovaných xxxxx;
XXXXX X XXXXXX XXXXXXXX XXX SOUTĚŽI |
Xxxxx xxxxxxxxx XX xx S5 x X1 až X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
S6. XXXXXXXXXXX
Všechna xxxxxxxxxxx (xxxxxx obou xxxxxx xxxxxxxxxx optických xxxxxxx) xxxx xxxxxxxx, s xxxxxxxx xxxxxxxx imidazoiu x xxxxxxx jejich xxxxxxxx použití a xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, amfepramon, xxxxxxxxxxx, xxxxxxxxx, amifenazol, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, fenetylin, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, klobenzorex, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, mefentermin, xxxxxxxxxxxx (x-), methylendioxyamfetamin, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, fenbutrazát, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující látky xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol, synefrin) xxxxxx považovány za Xxxxxxxx látky.
** Xxxxxxx podání xxxxxxxxxx (xxxx. nosní, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx vyšší xxx 5 mikrogramů x 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
S8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx a marihuana) xxxx syntetický delta9tetrahydrokanabinol (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /obsahující XXX018, XXX073/ x XX-210) xxxx xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, nitrožilní nebo xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
XXXXX XXXXXXXX X URČITÝCH XXXXXXXX |
P1. XXXXXXX
Xxxxxxx (etanol) xx zakázaný xxxxx Xxx Soutěži v xxxxxxxxxxxxx sportech. Detekce xx bude xxxxxxxx xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (WKF)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Xxxxx xxxx jinak určeno, xxxx-xxxxxxxxx jsou zakázány xxxxx Při Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxxx (FMB)
∙ Xxxx (XXX)
∙ Xxxxxxx a xxxxxxx (FIQ)
∙ Xxxxxxx sporty a xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx xxxx Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx xxx"
∙ Xxxxxxxx x xxxxxxx sporty (XXXX)
∙ Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)
∙ Xxxxx (XXX)
∙ Xxxxx motorismus (XxX)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Acebutolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metipranolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx ne x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 97/2012 Sb. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx předpis č. 97/2012 Sb. m. x. byl zrušen xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx xx 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.